Breaking News Instant updates and real-time market news.

INSY

Insys Therapeutics

$11.87

-0.34 (-2.78%)

06:52
10/13/16
10/13
06:52
10/13/16
06:52

Insys Therapeutics sees preliminary Q3 revenues from Subsys $54M-$55M

Insys Therapeutics' preliminary estimated Q3 revenues from Subsys sublingual spray will be $54M-$55M. The company believes it will be cash-flow positive at this level of sales and will be able to meet its overall objectives of new product development and future growth. Estimated revenues for the quarter reflect a decline in prescriptions as the company continues to believe that the ongoing and heightened publicity surrounding the national opioid epidemic and continuing governmental and regulatory scrutiny of the company and the transmucosal immediate release fentanyl class has resulted in a sensitivity by some healthcare providers to prescribe and dispense TIRF medications.

  • 29

    Nov

INSY Insys Therapeutics
$11.87

-0.34 (-2.78%)

04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/16
JANY
07/05/16
NO CHANGE
Target $22
JANY
Buy
Insys approval of Syndros may trigger short squeeze, says Janney Capital
Janney Capital analyst Ken Trbovich said in a note published on July 1 that the potential approval of Syndros was one of three potential catalysts expected in the next six months that may trigger a short squeeze in shares of Insys Therapeutics. Insys announced this morning that the FDA has approved Syndros for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. In his prior note, Trbovich set a $22 fair value estimate and Buy rating on Insys shares, which are up 20% to $16.18 in pre-market trading.
08/04/16
JEFF
08/04/16
NO CHANGE
Target $22
JEFF
Buy
Insys Therapeutics price target raised to $22 from $17 at Jefferies
Jefferies analyst David Steinberg raised his price target for Insys Therapeutics to $22 saying Subsys scripts appear to have stabilized following the company's in-line Q2 results. The most important element of earnings call was the comment that "we're very optimistic that it [settlement with the DOJ] could happen by end of the year," Steinberg tells investors in a research note. The analyst views the Department of Justice investigation as "by far the most important overhang to the story." He keeps a Buy rating on Insys.
08/26/16
JANY
08/26/16
NO CHANGE
Target $22
JANY
Buy
Illinois 'highly unlikely' to be able to bar Insys sales, says Janney Capital
Janney Capital analyst Ken Trbovich said he thinks it is "highly unlikely" that Illinois' Attorney General will succeed with her proposal to ban Insys Therapeutics from doing business in the state, pointing to the fact that a similar attempt by Massachusetts in 2014 was struck down by a federal judge. This story, and the trading in its wake yesterday, clearly indicate Insys has headline risks from ongoing state and federal investigations, acknowledged Trbovich, but he thinks the risk will be eliminated by a settlement for an amount the company can manage from its existing cash. The analyst keeps a Buy rating and $22 fair value estimate on Insys shares, which fell about 4.6% yesterday to close at $14.98.

TODAY'S FREE FLY STORIES

GS

Goldman Sachs

$249.02

1.67 (0.68%)

, TAL

TAL Education

$85.58

0.33 (0.39%)

13:51
02/27/17
02/27
13:51
02/27/17
13:51
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs, TAL Education »

Goldman Sachs reports…

GS

Goldman Sachs

$249.02

1.67 (0.68%)

TAL

TAL Education

$85.58

0.33 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 03

    Mar

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

, VCYT

Veracyte

$7.95

0.06 (0.76%)

13:50
02/27/17
02/27
13:50
02/27/17
13:50
Recommendations
Myriad Genetics, Veracyte analyst commentary  »

Piper sees CMS halt of…

MYGN

Myriad Genetics

$18.98

-0.07 (-0.37%)

VCYT

Veracyte

$7.95

0.06 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

13:50
02/27/17
02/27
13:50
02/27/17
13:50
General news
Treasury Action: yield have spiked higher as rate hike fears flare up »

Treasury Action: yield…

LJPC

La Jolla

$19.87

1.65 (9.06%)

13:39
02/27/17
02/27
13:39
02/27/17
13:39
Recommendations
La Jolla price target raised to $40 from $27 at Jefferies »

Jefferies analyst Eun…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

NH

NantHealth

$7.54

-0.08 (-1.05%)

, MDRX

Allscripts

$12.05

-0.11 (-0.90%)

13:33
02/27/17
02/27
13:33
02/27/17
13:33
Hot Stocks
CTCA partners with Allscripts, NantHealth to launch Clinical Pathways »

Cancer Treatment Centers…

NH

NantHealth

$7.54

-0.08 (-1.05%)

MDRX

Allscripts

$12.05

-0.11 (-0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

VRAY

ViewRay

$4.76

0.01 (0.21%)

13:30
02/27/17
02/27
13:30
02/27/17
13:30
Recommendations
ViewRay analyst commentary  »

ViewRay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 06

    Mar

AIG

AIG

$63.97

0.34 (0.53%)

13:29
02/27/17
02/27
13:29
02/27/17
13:29
Periodicals
AIG board to discuss whether to penalize or oust CEO over Q4 numbers, WSJ says »

AIG's directors are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

HAIN

Hain Celestial

$34.61

-0.23 (-0.66%)

13:26
02/27/17
02/27
13:26
02/27/17
13:26
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:19
02/27/17
02/27
13:19
02/27/17
13:19
Downgrade
bluebird bio rating change  »

Follow-up: bluebird bio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

$NSD

NASDAQ Market Internals

13:17
02/27/17
02/27
13:17
02/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
02/27/17
02/27
13:16
02/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$82.00

3.7 (4.73%)

13:15
02/27/17
02/27
13:15
02/27/17
13:15
Downgrade
bluebird bio rating change  »

bluebird bio downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

STM

STMicroelectronics

$15.49

0.485 (3.23%)

13:06
02/27/17
02/27
13:06
02/27/17
13:06
Options
STMicroelectronics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$81.47

0.385 (0.47%)

13:05
02/27/17
02/27
13:05
02/27/17
13:05
Periodicals
Exxon CEO sees rising Permian production, continued Russia presence, Forbes says »

Speaking in a Forbes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

SAFM

Sanderson Farms

$94.44

-0.72 (-0.76%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Conference/Events
Sanderson Farms management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

DDAIF

Daimler AG

$72.92

-0.39 (-0.53%)

13:01
02/27/17
02/27
13:01
02/27/17
13:01
Hot Stocks
Daimler names Martin Daum head of Trucks, Buses divisions »

Daimler said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMM

3M

$186.67

-0.7399 (-0.39%)

13:00
02/27/17
02/27
13:00
02/27/17
13:00
Hot Stocks
IPTAB upholds validity of 3M Korean patent »

The Intellectual Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

trivago

$12.85

-0.13 (-1.00%)

12:57
02/27/17
02/27
12:57
02/27/17
12:57
Conference/Events
trivago management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

12:55
02/27/17
02/27
12:55
02/27/17
12:55
Hot Stocks
Samsung says new Facebook app available for Samsung TVs »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SNAP

Snap Inc.

12:52
02/27/17
02/27
12:52
02/27/17
12:52
Hot Stocks
Snap Inc: Some Class A shares subject to separate lock-up »

In an amended IPO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

MRVL

Marvell

12:51
02/27/17
02/27
12:51
02/27/17
12:51
Options
Notable premium seller in Marvell Tech »

Notable premium seller in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 10

    Mar

  • 04

    Apr

  • 05

    Apr

WLL

Whiting Petroleum

$10.95

0.15 (1.39%)

12:46
02/27/17
02/27
12:46
02/27/17
12:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

CLSD

Clearside Biomedical

$8.06

1.16 (16.81%)

12:45
02/27/17
02/27
12:45
02/27/17
12:45
Conference/Events
Clearside Biomedical has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SBGSY

Schneider Electric

$13.49

-0.21 (-1.53%)

12:44
02/27/17
02/27
12:44
02/27/17
12:44
Conference/Events
Schneider Electric management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 02

    Mar

  • 03

    Mar

MTB

M&T Bank

$168.14

-0.535 (-0.32%)

12:37
02/27/17
02/27
12:37
02/27/17
12:37
Hot Stocks
M&T Bank announces passing of COO Mark Czarnecki »

M&T Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.